

ASX RELEASE

19 September 2019

Harvest One Cannabis Investor Presentation

MMJ Group Holdings Limited (ASX: MMJ) (MMJ or the Company) are pleased to provide the presentation which was delivered by Harvest One Cannabis Inc (“HVT”) (OTCQX: HRVOF | TSX-V: HVT) at the KCSA Cannabis Investor Conference on 12 September 2019.

MMJ holds 26%¹ of HVT and represents the largest investment within the MMJ cannabis and hemp portfolio.

This presentation covers HVT’s eight global operations – in Canada, the United States, Europe, Israel, and the Asia Pacific - and the progress in rolling out its business plan.

HVT is a global consumer packaged goods company that develops and distributes premium health, wellness, and selfcare products to patients and consumers in regulated markets around the world with a specific focus on sleep, anxiety and pain.

MMJ is confident that the experienced HVT management team will execute on its future business plan and that this should lead to an increase in the value of MMJ’s shareholding in Harvest One.

As HVT is one of the leading globally diversified companies in this sector we recommend the presentation as a comprehensive overview of strategically located regulated markets around the globe.

The attached HVT investor presentation is also available on MMJ’s website.

Investor and Media Enquiries

Jim Hallam
Chief Financial Officer and Company Secretary

About MMJ

MMJ is a global cannabis investment company (ABN 91 601 236 417). MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ’s latest investor presentation and news, please visit: <https://www.mmjgh.com.au/investors/>

Important Notice

This announcement contains reference to certain intentions, expectations, future plans, strategy and prospects of MMJ. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of MMJ may be influenced by a number of factors, many of which are outside the control of MMJ. No representation or warranty, express or implied, is made by MMJ, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause MMJ’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. MMJ does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in MMJ. This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). MMJ’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

¹ MMJ holds 55,557,994 HVT shares as at 19 September 2019



HARVEST ONE

A GLOBAL PORTFOLIO OF BRANDS



DISCLAIMER

The information found herein, and any other materials provided by Harvest One Cannabis Inc. (the “Company”), are intended solely for discussion purposes and are not intended as, and do not constitute, an offer to sell or a solicitation of an offer to buy any security, and should not be relied upon by you in evaluating the merits of investing in any securities. These materials are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use is contrary to local law or regulation. This information is confidential and should not be distributed, in whole or in part, beyond the recipient and its advisors.

The Company believes the information contained in this document to be reliable but makes no warranty or representation, whether express or implied, and assumes no legal liability for the accuracy, completeness or usefulness of any information disclosed. Any estimates, investment strategies, and views expressed in this document are based upon current market conditions and/or data and information provided by unaffiliated third parties and is subject to change without notice.

This document may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements about strategic plans, including the Company's ability to implement its business development strategy.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward- looking statements are not guarantees of future performance.

All forward- looking information contained herein are given as of the date hereof and are based upon the opinions and estimates of management and information available to management as at the date hereof. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Company from third parties, including but not limited to market data. The Company believes such information to be accurate but has not independently verified such information. To the extent such information was obtained from third party sources, there is a risk that the assumptions made, and conclusions drawn by the Company based on such representations are not accurate.

*All currency amounts are in Canadian dollars unless stated otherwise.


WHO WE ARE...

Harvest One is a global consumer packaged goods company that develops and distributes premium health, wellness, and selfcare products to patients and consumers in regulated markets around the world with a specific focus on sleep, anxiety and pain

PORTFOLIO OF COMPANIES



GLOBAL FOOTPRINT



Markets


Strategically located in select regulated markets around the globe.



OVERVIEW

- Vertically integrated licensed producer regulated by Health Canada
- Premium products for the recreational and medical markets
- Targeting 20,000 kg capacity of premium craft flower by end of 2019
- Additional supply secured to support extraction strategy
- Supply agreements with British Columbia, Ontario, Saskatchewan, & Manitoba
- Supply agreement with Shoppers Drug Mart for medical cannabis
- Extraction agreement with Valens GroWorks to advance product
- Product development underway for derivatives, including vape pens, topicals, and select edibles in regulated markets

Current Distribution Profile 4 Provincial Partners



Our Brands



DIVERSIFIED CULTIVATION OPERATIONS

Duncan Facility - BC



INDOOR

Premium indoor craft-grown BC flower

- 16,000 sq ft existing facility
- 13 acres of additional land for expansion
- 1,200 kg per year
- Expansion near completion; increasing capacity to 3,500 kg per year

Lucky Lake Facility - SK



INDOOR & OUTDOOR

Premium indoor craft-grown flower with potential outdoor cultivation

- 68,000 sq ft facility
- 23 acres of additional land for expansion
- 11,000 kg per year
- Retrofit underway; completion & licensing anticipated Q4 2019

Greenbelt Greenhouse - ON



GREENHOUSE & EXTRACTION

Extraction production to support derivative products

- 152,000 sq ft green house
- 42,000 sq ft processing facility
- 15,000 kg per year
- Retrofit underway; completion & licensing anticipated Q2 2020

satipharm



WE DO CBD DIFFERENTLY

OVERVIEW

- Satipharm is our medical and nutraceutical division
- Specializes in the development and manufacturing of cannabinoid-based health and wellness products
- Selling throughout Europe with major retailers including Holland & Barrett (Europe's largest retailer of wellness products)
- Distribution agreement with Health House for the Australian, New Zealand and Asian markets where regulations permit
- Supply Agreement with GenCanna (one of the largest U.S. hemp extractors) for GMP Certified CBD oil and finished products
- Plan to launch sales in Canada in early 2020

satipharm

Gelpell®



GELPELL® TECHNOLOGY

- Gelpell® Microgel Capsule process produces 2 mm gelatin beads containing a payload of cannabinoids
- Contains full spectrum CBD hemp-based extract including terpenes and flavonoids
- When ingested, the gelatin beads create a micro-emulsion which enhances bioavailability and the body's absorption of CBD
- The beads bypass the stomach and release in the lower intestine which helps ensure accurate and consistent dosing
- The beads are encapsulated and packaged under Swiss GMP protocols into 10 mg and 50 mg capsules

Satipharm Gelpell® technology **increases bioavailability of CBD** and the body's absorption of cannabinoids.

30% Higher
Bioavailability

Higher **Stability**

Full spectrum CBD hemp extract




CLINICAL TRIALS – Using Gelpell® Capsules

PHASE 1: Bioavailability & Stability

- Trial undertaken to prove bioavailability and stability
- Study in direct comparison to GW Pharma’s Sativex product
- Published in international medical journal, "Clinical Pharmacology in Drug Development", in 2017

RESULTS

- ✓ Demonstrable safety and tolerability profile with no significant side effects
- ✓ 30% higher bioavailability in comparison to GW Pharmaceuticals oromucosal spray – Sativex
- ✓ 8 hours exposure time in the blood
- ✓ 67% bioavailability



PHASE 2: Treatment of Pediatric Epilepsy

- Aimed at measuring safety and efficacy of Satipharm CBD capsules for reducing seizure frequency in children with refractory, or treatment-resistant epilepsy
- Published in peer reviewed medical journal, "Epilepsy & Behavior", in 2019

RESULTS

- ✓ The median reduction in monthly seizures was -82%
- ✓ 56% of patients had a reduction of at least 50% in total number of seizures
- ✓ 73% of patients were rated as “very much improved/improved” in overall condition
- ✓ Two patients were fully seizure-free within 5 weeks of treatment

satipharm

Gelpell®



Good Agricultural Collecting Practices

SHOPPERS DRUG MART – Supply Agreement




Satipharm Branded Cannabis

- Shoppers Drug Mart is the leading drug store retailer in Canada with more than 1,300 stores
- Satipharm cannabis available through Shoppers online in Ontario and Alberta
- Satipharm cannabis currently cultivated through United Greeneries
- Only 12 Licensed Producers have agreements with Shoppers
- Two initial varieties available - Indica variety of SatiSilver™ and a hybrid variety of SatiGreen™



The SatiSeries



PROPOSED PRODUCT PIPELINE



Dream[®] Water



OVERVIEW



- All natural sleep aid
- Sold in over 30,000 outlets
- First mover in the global OTC sleep aid market worth \$2.5 billion annually
- Health Canada and FDA approved
- Currently sold through industry leading retailers including:
 - Walmart US, Kroger, CVS, Shoppers Drug Mart, 7-11, Circle K
- CBD based formulations currently undergoing stability testing
- Innovative product line extensions including beauty & sports recovery SKU's (see next page)




PRODUCT LINE EXTENSIONS






DELIVRA : A Driving Force in Transdermal Delivery



DELIVRA SYSTEM

- Proprietary transdermal delivery system shuttles pharmaceutical and natural molecules through the skin in a targeted and specific manner
- Strong IP with 7 patent-pending applications (4 registered)
- Delivra's base platform is manufactured using many plant-based extracts (as well as synthetic drugs under GMP-certified manufacturing) to yield liquid crystals and a polymeric water-oil emulsion used to maintain stability of the product during its life cycle
- Delivra Plus delivery platform uses FDA approved non-medicinal ingredients for a worldwide finished product (i.e. Advil Ibuprofen cream)



PRODUCT PORTFOLIO



+



DreamWater

delivra™



Logos for various retailers under DreamWater distribution:

- Walmart
- LONDON DRUGS
- PHARMASAVE
- SHOPPERS DRUG MART
- Loblaws
- Albertsons SAFEWAY
- Sobeys Pharmacy
- CVS Health
- amazon.com
- Rexall
- meijer
- TOPS
- Hudson News
- Kroger
- Winn-Dixie BILO
- cornerstore
- 7 ELEVEN
- Core-Mark
- GSC
- cornerstore
- Pilot FLYING J
- Big Y
- FOUR SEASONS Hotels and Resorts
- Fairmont HOTELS & RESORTS

Logos for various retailers under delivra™ distribution:

- Walmart
- LONDON DRUGS
- PHARMAPRIX
- PHARMASAVE
- Jean Coutu
- SHOPPERS DRUG MART
- Loblaws
- FORTINOS
- Lawtons DRUGS
- Guardian
- Rexall
- Sobeys Pharmacy
- I.D.A.
- Brunet



Multiple products in over 38,000 Stores

United greeneries

satipharm*



Logos for various retailers under United greeneries distribution:

- BC CANNABIS STORES
- Saskatchewan Liquor and Gaming Authority
- ONTARIO CANNABIS STORE
- MANITOBA LIQUOR & LOTTERIES

Logos for various retailers under satipharm* distribution:

- shopify
- Chemist Direct
- Health House
- HL PHARMA
- HOLLAND & BARRETT
- SHOPPERS DRUG MART



GEOGRAPHICAL EXPANSION

NORTH AMERICA

- Dream Water - expand current products + CBD SKU
- Introduce LivRelief™ to U.S., including CBD SKU
- Introduce Satipharm products



EUROPE

- Dream Water EU - compliant SKU
 - Already in negotiations with large distribution partner
- Satipharm – expanding product lines
- Introduce LivRelief™ including CBD SKU

SOUTH AMERICA

- Enter market through established distribution partner
- Introduce Dream Water including CBD SKU
- Introduce LivRelief™ including CBD SKU
- Introduce Satipharm products



ASIA & AUSTRALIA

- Strengthen distribution that already includes agreement with distribution partner Health House
- Expanding Satipharm product offerings
- Introduce Dream Water including CBD SKU
- Introduce LivRelief™ including CBD SKU

EXISTING & FUTURE PRODUCTS



Brand	Flower	Vape Pens	Oil	Topicals	Edibles	Gelpell®	Pets	Cosmeceuticals	Innovation	Non Cannabis
 ROYAL HIGH	●	●	●	●	●				●	
 CAPTAIN'S CHOICE	●		●	●	●				●	
 satipharm	●	●	●	●		●			●	
 DreamWater				●	●				●	●
 Dr. Joe's LivRelief™				●					●	●
 New Brands							●	●	●	

bur'b



GOING RETAIL: BURB

- Initial investment - 20% ownership (maximum allowed by BC regulations)
- Estimating opening 8 -10 retail outlets in British Columbia
- Received municipality permitting for 2 stores in Port Coquitlam, BC
- First store opened on April 20, 2019 and is currently selling apparel
- BC provincial licensing imminent
- Further expansion planned throughout Canada including Alberta, Saskatchewan and Ontario
- Robust brand merchandising strategy in place to support luxury brand



Grant Froese
CEO



Andrew Kain
COO & General Counsel



Aaron Wong
CFO



Nick Maltchev
CTO



Deb Milimaka Miles
CAO & CPO



Andy Bayfield
CCO



Will Stewart
SVP Corporate &
Public Affairs



David Hyde
Advisory Board



Todd Dea
President of United
Greeneries



Tucker Wright
President of Dream Water



Jonathan Hartshorn
President of Satipharm



Dr. Joseph Gabriele
President of Delivra



SELECT EXPERIENCE WITHIN OUR TEAM



FINANCIAL INFORMATION

TSX V: HVT OTCQX: HRVOF

CAPITAL STRUCTURE

Market Capitalization	\$111m
Issued Shares	215m
Warrants	35.9m (\$0.59-\$2.30)
Options	20.3m
Cash	\$30m (As of March 31, 2019)
Debt	\$280k (As of March 31, 2019)
52 week Low/High	\$0.32 - \$1.15
Insider Holdings	Approx 26% (MMJ Holding)
30 Day Average Volume	283,262

ANALYST COVERAGE

Firm	Analyst	
Haywood Securities	Neal Gilmer	
Mackie Research	Greg McLeish	

* All figures in CAD as of September 6th, 2019

FUTURE CATALYSTS

- Scaling up – three expansions coming online
- New derivative products coming online in Canada and the United States
- New CBD formulations of Dream Water and LivRelief™
- LivRelief™ to begin selling in the United States
- Satipharm Gelpell capsules (CBD and THC) launching in Canada
- Large scale extraction and manufacturing expansion
- Geographical expansion in Europe and LATAM



Dream
Water



satipharm

THANK YOU!

Contact Information:

Investor Relations

Phone: +1 (877) 915 7934

